Ravasio R, Viti R, Roscini AS. Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy. AboutOpen [Internet]. 2023 Jan. 16 [cited 2024 Nov. 23];10(1):13-21. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2515